Zelira Therapeutics: Launches Zenivol in Australia

  • Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
  • The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
  • Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
  • This announcement follows a successful clinical trial conducted by the University of Western Australia
  • Zelira is on track to launch five new products across global markets in 2020
  • Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Experian Launches Credit Score App in ChatGPT, Enhancing Financial Access

New tool enables users to check credit scores effortlessly via ChatGPT.Highlights: Experian's app allows users to check credit...

US Senate Passes Bill Banning Issuance of CBDCs

Legislation aims to restrict the development of digital currencies by the Federal Reserve.Highlights: The US Senate approved a...

Truist Expands Open Banking Offerings with Plaid Partnership

Collaboration aims to enhance customer access to financial services.Highlights: Truist collaborates with Plaid for open banking expansion.The partnership...

UK’s National Fraud Database Reports 444,000 Fraud Cases in 2025

Cifas reveals a significant rise in reported fraud incidents across the UK.Highlights: Cifas reported 444,000 fraud cases in...